Patients in GLP-1 trials spontaneously reduced alcohol intake, gambling, and even online shopping without being prompted. Lilly is now pursuing a Phase 3 drug — brenepatide — specifically for alcohol use disorder, as the mechanism appears to quiet hedonic urges broadly.